- Home
- MDGL vs BXSL Comparison
MDGL vs BXSL Comparison
Compare MDGL & BXSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- BXSL
- Stock Information
- Founded
- MDGL 2011
- BXSL 2018
- Country
- MDGL United States
- BXSL United States
- Employees
- MDGL N/A
- BXSL N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- BXSL Trusts Except Educational Religious and Charitable
- Sector
- MDGL Health Care
- BXSL Finance
- Exchange
- MDGL Nasdaq
- BXSL Nasdaq
- Market Cap
- MDGL 6.1B
- BXSL 7.3B
- IPO Year
- MDGL N/A
- BXSL N/A
- Fundamental
- Price
- MDGL $302.17
- BXSL $31.15
- Analyst Decision
- MDGL Strong Buy
- BXSL Buy
- Analyst Count
- MDGL 9
- BXSL 6
- Target Price
- MDGL $420.63
- BXSL $31.38
- AVG Volume (30 Days)
- MDGL 371.3K
- BXSL 830.6K
- Earning Date
- MDGL 08-05-2025
- BXSL 08-06-2025
- Dividend Yield
- MDGL N/A
- BXSL 9.87%
- EPS Growth
- MDGL N/A
- BXSL N/A
- EPS
- MDGL N/A
- BXSL 3.14
- Revenue
- MDGL $317,383,000.00
- BXSL $1,380,706,000.00
- Revenue This Year
- MDGL $286.67
- BXSL $9.58
- Revenue Next Year
- MDGL $67.98
- BXSL $3.71
- P/E Ratio
- MDGL N/A
- BXSL $9.94
- Revenue Growth
- MDGL N/A
- BXSL 16.76
- 52 Week Low
- MDGL $200.63
- BXSL $25.89
- 52 Week High
- MDGL $377.46
- BXSL $34.64
- Technical
- Relative Strength Index (RSI)
- MDGL 48.85
- BXSL 39.48
- Support Level
- MDGL $286.44
- BXSL $31.44
- Resistance Level
- MDGL $312.05
- BXSL $32.20
- Average True Range (ATR)
- MDGL 14.84
- BXSL 0.46
- MACD
- MDGL -3.14
- BXSL -0.12
- Stochastic Oscillator
- MDGL 22.01
- BXSL 9.78
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About BXSL Blackstone Secured Lending Fund of Beneficial Interest
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.